| Size | Price | |
|---|---|---|
| Other Sizes |
| Targets |
Fmoc-Phe(4-Br)-OH is a synthetic building block for peptide synthesis and does not have a specific biological receptor target. Its primary application is in the preparation of brominated phenylalanine-containing peptides for structure-activity relationship (SAR) studies, protein-protein interaction research, and biomaterial development. The para-bromo substituent can modulate peptide hydrophobicity and enable halogen bonding interactions in target binding studies.
|
|---|---|
| ln Vitro |
In vitro activity of Fmoc-Phe(4-Br)-OH is not applicable as a standalone biological agent. It functions as a peptide synthesis reagent rather than a directly bioactive compound. Peptides synthesized using this building block can be evaluated for various biological activities including enzyme inhibition, receptor modulation, and antimicrobial effects. The brominated phenylalanine residue can enhance target binding through halogen bonding and hydrophobic interactions.
|
| ln Vivo |
In vivo activity data for Fmoc-Phe(4-Br)-OH as a standalone compound are not applicable, as it is a research building block for peptide synthesis. Brominated phenylalanine-containing peptides synthesized using this reagent may be evaluated in animal models for therapeutic applications. The D- or L-configuration and halogen substitution can influence peptide stability and bioactivity in vivo.
|
| Enzyme Assay |
Standard SPPS protocols for Fmoc-Phe(4-Br)-OH involve activation with coupling reagents such as HATU or HBTU (1 equiv) and DIPEA (2 equiv) in DMF, followed by coupling to resin-bound peptides. Fmoc deprotection is achieved using 20% piperidine in DMF. Coupling efficiency is monitored by HPLC or Kaiser test. Purity is typically ≥98.0% by HPLC. The compound has a molecular weight of 466.32 g/mol and melting point of 151.5°C.
|
| Cell Assay |
Cell-based protocols are not directly applicable to Fmoc-Phe(4-Br)-OH as it is a peptide synthesis building block. Brominated phenylalanine-containing peptides synthesized using this reagent can be tested in cell culture. Peptides are dissolved in DMSO or appropriate buffers, sterile-filtered, and added to cells at concentrations of 0.1-100 µM. Incubation is typically 24-72 hours. Assays include cell viability (MTT), proliferation, apoptosis, and specific signaling pathway readouts.
|
| Animal Protocol |
Animal studies with Fmoc-Phe(4-Br)-OH are not conducted directly as it is a research building block. Peptides containing 4-bromophenylalanine residues synthesized using this compound may be evaluated in vivo. Protocols involve administration of the peptide via appropriate routes (IV, IP, PO) in animal models. Pharmacokinetic sampling, efficacy assessment, and toxicological evaluation follow standard preclinical study designs. The brominated residue can influence peptide stability and target binding.
|
| ADME/Pharmacokinetics |
Pharmacokinetic data for Fmoc-Phe(4-Br)-OH as a standalone compound are not applicable. The compound has a molecular weight of 466.32 g/mol, formula C₂₄H₂₀BrNO₄, and density of 1.459 g/cm³. It is soluble in standard SPPS solvents like DMF. Storage is recommended at 2-8°C. The Fmoc group is removed under basic conditions during peptide synthesis.
|
| Toxicity/Toxicokinetics |
Limited toxicity data is available for Fmoc-Phe(4-Br)-OH as it is a research chemical. The compound has an Aquatic Chronic 4 hazard classification. Standard safety precautions for handling Fmoc-protected amino acids should be observed. The compound is not intended for human therapeutic use. Store as powder at 2-8°C. Proper personal protective equipment should be worn when handling.
|
| References | |
| Additional Infomation |
Fmoc-Phe(4-Br)-OH (CAS#: 198561-04-5) is also known as N-α-(9-Fluorenylmethoxycarbonyl)-4-bromo-L-phenylalanine, (S)-N-Fmoc-4-bromophenylalanine, and Fmoc-L-4-Bromophenylalanine. Its IUPAC name is (2S)-3-(4-bromophenyl)-2-(9H-fluoren-9-ylmethoxycarbonylamino)propanoic acid. It is used in the synthesis of compounds, protein-protein interaction studies, and biomaterial development. It has no approved therapeutic indications.
|
| Molecular Formula |
C24H20BRNO4
|
|---|---|
| Molecular Weight |
466.3239
|
| Exact Mass |
465.057
|
| CAS # |
198561-04-5
|
| PubChem CID |
2734449
|
| Appearance |
White to off-white powder
|
| Density |
1.5±0.1 g/cm3
|
| Boiling Point |
660.8±55.0 °C at 760 mmHg
|
| Melting Point |
151.5 °C
|
| Flash Point |
353.4±31.5 °C
|
| Vapour Pressure |
0.0±2.1 mmHg at 25°C
|
| Index of Refraction |
1.647
|
| LogP |
6.18
|
| Hydrogen Bond Donor Count |
2
|
| Hydrogen Bond Acceptor Count |
4
|
| Rotatable Bond Count |
7
|
| Heavy Atom Count |
30
|
| Complexity |
584
|
| Defined Atom Stereocenter Count |
1
|
| SMILES |
BrC=1C=CC(=CC1)C[C@@H](C(O)=O)NC(OCC2C3=CC=CC=C3C4=CC=CC=C42)=O
|
| InChi Key |
TVBAVBWXRDHONF-QFIPXVFZSA-N
|
| InChi Code |
InChI=1S/C24H20BrNO4/c25-16-11-9-15(10-12-16)13-22(23(27)28)26-24(29)30-14-21-19-7-3-1-5-17(19)18-6-2-4-8-20(18)21/h1-12,21-22H,13-14H2,(H,26,29)(H,27,28)/t22-/m0/s1
|
| Chemical Name |
(2S)-3-(4-bromophenyl)-2-(9H-fluoren-9-ylmethoxycarbonylamino)propanoic acid
|
| Synonyms |
Fmoc-Phe(4-Br)-OH
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.1445 mL | 10.7223 mL | 21.4445 mL | |
| 5 mM | 0.4289 mL | 2.1445 mL | 4.2889 mL | |
| 10 mM | 0.2144 mL | 1.0722 mL | 2.1445 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
